The estimated Net Worth of John Gary Potthoff is at least 69.4 千$ dollars as of 24 June 2021. John Potthoff owns over 16,314 units of Chembio Diagnostics stock worth over 24,880$ and over the last 6 years he sold CEMI stock worth over 0$. In addition, he makes 44,500$ as Independent Director at Chembio Diagnostics.
John has made over 3 trades of the Chembio Diagnostics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 16,314 units of CEMI stock worth 7,504$ on 24 June 2021.
The largest trade he's ever made was buying 20,000 units of Chembio Diagnostics stock on 14 November 2018 worth over 116,200$. On average, John trades about 7,719 units every 159 days since 2018. As of 24 June 2021 he still owns at least 54,086 units of Chembio Diagnostics stock.
You can see the complete history of John Potthoff stock trades at the bottom of the page.
Dr. John Gary Potthoff Ph.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Dr. Potthoff has 25 years of experience in the clinical research services industry, with deep ties to diagnostics and pharmaceutical companies. He is currently the CEO of Elligo Health Research, a clinical research company aimed at being the preeminent provider of clinical research infrastructure services and technologies. Prior to Elligo, Dr. Potthoff was the CEO of Theorem Clinical Research, where he led the company through a period of significant growth and its acquisition by Chiltern International. Previously, Dr. Potthoff was the CEO and founder of Tanistry, Inc., a contract research organization focused on the central nervous system.
As the Independent Director of Chembio Diagnostics, the total compensation of John Potthoff at Chembio Diagnostics is 44,500$. There are 5 executives at Chembio Diagnostics getting paid more, with Javan Esfandiari having the highest compensation of 557,521$.
John's mailing address filed with the SEC is C/O CHEMBIO DIAGNOSTICS, INC., 3661 HORSEBLOCK ROAD, MEDFORD, NY, 11763.
Over the last 20 years, insiders at Chembio Diagnostics have traded over 909,824$ worth of Chembio Diagnostics stock and bought 3,754,893 units worth 1,696,058$ . The most active insiders traders include Credit Advisors, Llcpercept...、Lawrence A. Siebert、Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of 36,203$. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth 109,552$.
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
Chembio Diagnostics executives and other stock owners filed with the SEC include: